Diagnostic precision with liquid biopsy for asymptomatic ovarian cancer

Reading time approx. 1 minute Publication type:
Share:

Ongoing Projects

SBU assess relevant and well-conducted research and investigate what effect different interventions have, if there are any risks or ethical problems, and what is most cost-effective in the areas of health care, dentistry, social services, and within the areas of functional disability and work environment.

Background

Liquid biopsy is a diagnostic method that allows to identify and measure very small amounts of free DNA or RNA sequences in body fluids, such as blood. The technique is considered precise enough that it could be used to detect and diagnose malignant tumors before the appearance of any symptoms, but also develop into an important marker for follow-up of different therapies. The method has developed rapidly and could within a near future be subject for clinical introduction.

Aim

The aim of this project is to study the accurary of liquid biopsies in detecting early, asymptomatic ovarian cancer. Early diagnostics of ovarian cancer are of particular interest as the prognose is heavily dependent on when the disease is discovered. If detected early the prognosis is often good. If, however, detected late the prognosis is considerably worse and altogether presents a significantly more complex condition to treat. Today most cases of ovarian cancer are diagnosed at a late stage.

Contact SBU
Registration no: SBU 2023/534
To top

Project group

Experts

Recruitment is currently ongoing.

From SBU

  • Jan Holst, Project Manager
  • Helena Domeij, Assistant Project Manager
  • Caroline Jungner, Project Administrator
  • Ann Kristine Jonsson, Information Specialist
  • Therese Eriksson, Health Economist
  • Jenny Odeberg, Head of Department
Page updated